You are here

GSK

Biopharma ramps up lobbying spend as drug pricing legislation nears

Biopharma ramps up lobbying spend as drug pricing legislation nears

Endpoints

Teva Pharmaceutical

Flag link:

GSK stops Keytruda combo trials after ICOS drug falls short

GSK stops Keytruda combo trials after ICOS drug falls short

Fierce Biotech

clinical trials

Flag link:

AZ aims at Pfizer, GSK with potential new PARP cancer drug

AZ aims at Pfizer, GSK with potential new PARP cancer drug

Pharmaforum

PARP inhibitors

Flag link:

GSK's ViiV Healthcare continues cabaret campaign to engage and inspire HIV community

GSK's ViiV Healthcare continues cabaret campaign to engage and inspire HIV community

Fierce Pharma

pharma marketing

ViiV Healthcare

Flag link:

GlaxoSmithKline offloads royalty rights for 2 cancer drugs in $342M windfall it will use to finance consumer spinoff

GlaxoSmithKline offloads royalty rights for 2 cancer drugs in $342M windfall it will use to finance consumer spinoff

Endpoints

Flag link:

GlaxoSmithKline, Novavax team up on COVID vaccine production in U.K., helping reduce dependence on AZ shot

GlaxoSmithKline, Novavax team up on COVID vaccine production in U.K., helping reduce dependence on AZ shot

Fierce Pharma

drug manufacturing

Flag link:

Eli Lilly, GlaxoSmithKline-Vir release positive but difficult-to-interpret combo antibody data

Eli Lilly, GlaxoSmithKline-Vir release positive but difficult-to-interpret combo antibody data

Endpoints

Vir Biotechnology

clinical trials

Flag link:

GlaxoSmithKline and Vir submit Covid-19 mAb for emergency authorization

GlaxoSmithKline and Vir submit Covid-19 mAb for emergency authorization

Endpoints

Vir Biotechnology

Emergency Use Authorization

monoclonal antibodies

Flag link:

FDA adds Guillain-Barré syndrome warning to GlaxoSmithKline’s shingles vaccine

FDA adds Guillain-Barré syndrome warning to GlaxoSmithKline’s shingles vaccine

Endpoints

Guillain-Barré Syndrome

Flag link:

Slaoui steps down from two more biotechs after harassment claim

Slaoui steps down from two more biotechs after harassment claim

BioPharma Dive

Centessa Pharmaceuticals

sexual harassment

Flag link:

Moncef Slaoui, former head of Operation Warp Speed, fired from company board over sexual harassment allegations

Moncef Slaoui, former head of Operation Warp Speed, fired from company board over sexual harassment allegations

Stat

Operation Warp Speed

sexual harassment

Flag link:

GSK flags new data suggesting a stark decline in routine adult vaccinations in the US

GSK flags new data suggesting a stark decline in routine adult vaccinations in the US

Biopharma Reporter

Flag link:

Boston Pharmaceuticals signs three-year agreement with GSK

Boston Pharmaceuticals signs three-year agreement with GSK

Pharmaceutical Business Review

Boston Pharmaceuticals

drug development

Flag link:

GSK, Merck KGaA's BTC Drug Fails for Second Time This Year

GSK, Merck KGaA's BTC Drug Fails for Second Time This Year

BioSpace

metastatic biliary tract cancer

bintrafusp alfa

Flag link:

GSK kick-starts phase 3 Medicago-partnered COVID vaccine test

GSK kick-starts phase 3 Medicago-partnered COVID vaccine test

Fierce Biotech

Flag link:

GSK, Novo and Roche meds hit pandemic potholes while Dupixent, Humira stood strong: analysts

GSK, Novo and Roche meds hit pandemic potholes while Dupixent, Humira stood strong: analysts

Fierce Pharma

Flag link:

Vir, GSK COVID-19 antibody slashes hospitalizations and deaths in phase 3, spurring FDA filing plans

Vir, GSK COVID-19 antibody slashes hospitalizations and deaths in phase 3, spurring FDA filing plans

Fierce Biotech

Vir Biotechnology

clinical trials

Flag link:

GlaxoSmithKline CEO Walmsley's pay falls to $9.7M as pandemic drags on profits

GlaxoSmithKline CEO Walmsley's pay falls to $9.7M as pandemic drags on profits

Fierce Pharma

Flag link:

GlaxoSmithKline's doctor payments double as relaxed policy plays out

GlaxoSmithKline's doctor payments double as relaxed policy plays out

Fierce Pharma

physician payments

Flag link:

Vir shares tumble after apparent setback for COVID-19 drug

Vir shares tumble after apparent setback for COVID-19 drug

BioPharma Dive

Vir Biotechnology

clinical trials

Flag link:

Pages